GlassScriptPhysician profile
Lauren A Slade
NPI 1437401288
$5,577.67
in general payments reported to CMS, 2019-2025
21 companies · $924 in 2025
The $924 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,024 · 2022: $1,455 · 2023: $979 · 2024: $1,197 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,099.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,663.75 | 2021-2025 | Pressurewire, Xience Skypoint, Xience Sierra |
| E.R. Squibb & Sons, L.L.C. | $585.50 | 2021-2025 | Camzyos, Eliquis |
| Atricure, INC. | $516.23 | 2021-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax, Synergy Ablation System |
| Biosense Webster, INC. | $453.46 | 2022-2025 | Carto 3, Octaray Mapping Catheter |
| Novartis Pharmaceuticals Corporation | $443.39 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $348.33 | 2021-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $325.31 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $324.40 | 2021-2024 | Farxiga, Wainua, Brilinta |
| Actelion Pharmaceuticals US, INC. | $186.55 | 2023-2025 | Uptravi, Opsumit |
| Abiomed | $178.27 | 2024-2025 | Impella |
| Amgen INC. | $105.35 | 2021-2024 | Repatha |
| Medtronic, INC. | $95.65 | 2021-2025 | Hawkone |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.93 | 2023-2025 | Jardiance |
| Boston Scientific Corporation | $64.06 | 2024 | Watchman Flx |
| Edwards Lifesciences Corporation | $63.89 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $52.92 | 2025 | |
| Ethicon US, LLC | $29.87 | 2025 | Surgicel Nu-Knit, Stratafix |
| Cardiva Medical, INC. | $24.96 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Bayer Healthcare Pharmaceuticals INC. | $16.79 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $12.88 | 2023 | Arcalyst |
| Biotronik INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Slade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.